Seattle Genetics strikes again with $208M ADC deal with Abbott

Seattle Genetics ($SGEN) has racked up another collaboration pact involving its closely-watched antibody-drug conjugate technology. The red-hot ADC company is pocketing $8 million from Abbott Laboratories ($ABT), which is promising up to $200 million more as it focuses on a single cancer target.

"This is the second ADC collaboration with a multinational pharmaceutical company that we have announced this year, further illustrating the important role that our ADC technology is poised to play in the treatment of many types of cancer," says Eric Dobmeier, the chief business officer of Seattle Genetics.

Abbott is responsible for research, product development, manufacturing and commercialization of any ADC products under the collaboration. Seattle Genetics has 11 active ADC collaborations which have spawned payments of more than $155 million from ADC licensing deals to date.

- here's the Seattle Genetics release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."